Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Dianthus Therapeutics (NASDAQ:DNTH) executives used a Biotech Summit 2026 discussion to outline upcoming clinical catalysts ...
The study of immune inflammatory responses centers on the intricate molecular pathways that both initiate and modulate these processes. Inflammation is ...
Why do we focus on the bad news stories about cuts and crises in classical music ? Musicians are doing incredible things to engage, support and sustain us; we should tell those stories too When did ...
Mr. Shinners is a pianist and harpsichordist and hosts the podcast “W.T.F. Bach.” Classical music has been in a crisis for decades. New generations don’t seem to care about it. The institutions that ...
Performances in N.Y.C. Advertisement Supported by Listen to recordings by Maria Dueñas and Daniil Trifonov, works by Thomas Adès and Tania León, and more. London Philharmonic Orchestra; Thomas Adès, ...
Pour one out for the ancient MetroCard and its equally old cousin, the PATH SmartLink card. The beginning of the end for these longtime ways to pay fares on the bi-state PATH system came Thursday when ...
NEW YORK, Nov 12 (Reuters) - The U.S. Food and Drug Administration can approve new personalized treatments for rare and deadly genetic diseases based on data from a handful of patients, two of the ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results